Nasir Shahab

Hepatotoxicity of chemotherapy.

The selection of a chemotherapeutic regimen for the oncology patient is based on a thorough assessment of potential hazards relating to the patient’s clinical condition and the toxicities of chemotherapy. Liver function abnormalities are commonly seen in this patient population and deducing their aetiology may be difficult. Immunosuppression, paraneoplastic phenomena, infectious disease, metastases and polypharmacy may all confound the clinical picture. While criteria for standardising liver injury have been established, dose modifications often rely on empirical clinical judgement. Therefore, a comprehensive understanding of hepatotoxic manifestations for the most common chemotherapeutic agents is essential. This article reviews the hepatotoxicity of commonly utilised antineoplastic agents.

Male breast cancer: Pathology, treatment, and outcome

814 Background: A single-institution retrospective review of the clinical/pathologic presentation, treatment, and outcome of male breast cancer was conducted. Methods: Data pertaining to clinical/pathologic presentation, treatment, and outcome were obtained by chart review of 21 male breast cancer patients from 1976–2004. Results: Patients presented at a median age of 67 years (34–90), with 71.4% presenting with a self-detected breast mass. Left sided breast cancer was present in 61.9% of patients and there were no reported cases of bilateral disease. The pathologic subtypes were infiltrating ductal carcinoma (80.9%), DCIS (9.5%), adenocarcinoma (4.7%), and intraductal papillary carcinoma (4.7%). Additionally, ER and PR positivity were 80.9 and 76.2% respectively, with 90.5% of tumors >1 cm in greatest diameter. Modified radical mastectomy was performed in 90.4% of patients revealing positive lymph nodes in 52.3% of patients. Adjuvant chemotherapy and/or hormonal therapy were prescribed in 23.8 and 47.6% ...

Rituximab is an effective treatment in cutaneous histiocyte predominant T-cell rich B-cell lymphoma

6744 Rituximab, an anti CD-20 monoclonal antibody, is efficacious in multiple subtypes of systemic B-cell non-Hodgkin’s lymphoma. Its use in cutaneous B-cell non-Hodgkin’s lymphomas is limited. Its...

Is Docetaxel Now an Essential Component of Neoadjuvant Breast Chemotherapy

REFERENCES 1. Cuzick J, Stewart H, Rutqvist L, et al: Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 12:447-453, 1994 2. EBCTCG: Favorable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Lancet 355:1757-1770, 2000 3. Erselcan T, Kairemo KJ, Wiklund TA, et al: Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer. Br J Cancer 82:777-781, 2000 4. Bergh J, Wiklund T, Erikstein B, et al: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomized trial—Scandinavian Breast Group 9401 Study. Lancet 356:1384-1391, 2000 5. Scandinavian Breast Group Study 9401: Long-term follow-up of the randomized Scandinavian Breast Group (SBG) study 9401 comparing standard FEC followed by marrow supported high-dose therapy versus tailored and dose-escalated FEC therapy. Proc Am Soc Clin Oncol 22:24a, 2003 (abstr 94) 6. Hernberg M, Virkkunen P, Maasilta P, et al: Pulmonary toxicity after radiotherapy in primary breast cancer patients: Results from a randomized chemotherapy study. Int J Radiat Oncol Biol Phys 52:128-136, 2002